Isotretinoin is an oral retinoid, a drug related to vitamin A. Roche sold it as Accutane, and the FDA approved it in 1982 for severe nodular acne that has not responded to other treatment, including antibiotics. It works mainly by shrinking the oil-producing (sebaceous) glands, and the label states that a single 15–20 week course gives complete and prolonged remission in many patients.

It appears in an anabolic steroid library because acne is one of the most common visible side effects of anabolic-androgenic steroids (AAS). The single most important fact about isotretinoin is that it causes severe birth defects. In the US it can be prescribed and dispensed only through a restricted program called iPLEDGE, and its label carries other serious warnings that matter to people who train hard or take other drugs that affect the liver and blood lipids.

This page summarizes what the FDA labels, clinical trials and regulators report. It is for education only and is not medical advice.

Property	Detail
Drug class	Retinoid (13-cis-retinoic acid), a vitamin A derivative
Original brand	Accutane (Roche), NDA 18-662, approved May 7, 1982; discontinued by Roche in 2009
Current US products	Generics and branded generics (Amnesteem, Claravis, Zenatane, Myorisan; an ANDA product now sold under the Accutane name), plus Absorica and Absorica LD
Route	Oral capsule
Labeled dose	0.5–1 mg/kg/day in two divided doses with food, for 15–20 weeks
Half-life (label)	About 21 h for isotretinoin; about 24 h for its main metabolite, 4-oxo-isotretinoin
Key mechanism fact	Shrinks sebaceous glands and cuts sebum output; the exact mechanism is unknown
US status	Prescription only, under the iPLEDGE REMS; not listed in Schedule III
WADA status	Not named on the 2026 Prohibited List

What it is

Isotretinoin is 13-cis-retinoic acid: formula C₂₀H₂₈O₂, molecular weight 300.4 g/mol (PubChem). It is a geometric isomer of tretinoin (all-trans-retinoic acid), and the two convert back and forth in the body. Both are related to retinol, the main form of vitamin A (Accutane label).

The first major clinical report was published in 1979 (Peck et al., NEJM 1979). They treated 14 patients with treatment-resistant cystic and conglobate acne for four months at an average of 2.0 mg/kg/day:

13 of 14 cleared completely, and the 14th improved by 75%.
All 14 stayed in remission, at that point for up to 20 months after stopping.
Side effects were mostly limited to the skin and mucous membranes and reversed quickly after stopping.

History of the Accutane brand

Date	Event
May 7, 1982	FDA approves Roche’s Accutane (NDA 18-662) for severe recalcitrant nodular acne
June 24, 2009	Roche notifies FDA that Accutane 10, 20 and 40 mg are being discontinued
July 7, 2010	FDA determines Accutane was not withdrawn for reasons of safety or effectiveness, so generics could stay on the market (75 FR 39024)
November 22, 2010	FDA withdraws Roche’s NDA at the company’s request because the product was no longer marketed (75 FR 71135)

The name “Accutane” is still in use: a current DailyMed listing from JG Pharma sells isotretinoin capsules (10, 20, 30 and 40 mg) under that brand, made under an abbreviated (generic) application, ANDA 202099 (Accutane label).

How it works

The label states that the exact mechanism is unknown. At 0.5–1 mg/kg/day it suppresses sebaceous gland function and keratinization (the build-up of skin cells that plugs pores). The drop in sebum output tracks the dose and length of treatment, and reflects smaller glands and blocked gland-cell differentiation.

One proposed mechanism is cell death in the gland. In skin biopsies from 7 patients, sebaceous gland cells were undergoing apoptosis (programmed cell death) after one week of treatment (Nelson et al., J Clin Invest 2008). In cultured human sebaceous cells, this effect depended on a protein called lipocalin 2 (NGAL). This is laboratory work, not proof of the full clinical mechanism.

Why it comes up with anabolic steroids

Androgens drive sebum production, and steroid-related acne is common. A 2007 German dermatology review estimated that acne occurs in about 50% of AAS users. It called acne an important clinical sign of AAS use, especially in young men aged 18–26, and noted that AAS can trigger severe forms such as acne conglobata and acne fulminans (Melnik et al., JDDG 2007).

We found no controlled trials of isotretinoin specifically in steroid-induced acne. The approved indication and all labeled dosing come from trials in ordinary severe nodular acne.

Pharmacokinetics

Isotretinoin is very fat-soluble, so food changes how much is absorbed. In a crossover study, 74 healthy adults took a single 80 mg dose with and without a high-fat meal (Accutane label):

Parameter	Fed (high-fat meal)	Fasted
Total exposure (AUC)	10,004 ng·h/mL	3,703 ng·h/mL
Peak level (Cmax)	862 ng/mL	301 ng/mL
Time to peak	5.3 h	3.2 h
Elimination half-life	21 h	21 h

Food more than doubled exposure without changing the half-life, which is why standard capsules are labeled to be taken with a meal. Other points from the label:

Binding: over 99.9% bound to plasma proteins, mostly albumin.
Metabolism: the liver enzymes CYP2C8, 2C9, 3A4 and 2B6 (in vitro data) convert it to 4-oxo-isotretinoin, tretinoin and 4-oxo-tretinoin. All have retinoid activity. At steady state, exposure to 4-oxo-isotretinoin is about 3.4 times that of isotretinoin.
Half-lives: 21 ± 8.2 h for isotretinoin and 24 ± 5.3 h for 4-oxo-isotretinoin in adults; 15.7 h for isotretinoin in children aged 12–15.
Elimination: metabolites leave in feces and urine in roughly equal amounts (65–83% of a radiolabeled dose in total). Total radioactivity in blood declined with a half-life of 90 hours.

Absorica and Absorica LD

Sun Pharma’s Absorica (NDA 021951) and Absorica LD (NDA 211913, micronized isotretinoin) are formulated so food matters less (Absorica label):

Product	Effect of a high-fat meal	Half-life: isotretinoin / 4-oxo metabolite
Absorica 40 mg	AUC about 50% higher, Cmax about 26% higher	18 h / 38 h
Absorica LD 32 mg	AUC about 20% higher, Cmax about 6% higher	About 24 h / 38 h

The label states that Absorica and Absorica LD are not interchangeable mg for mg, because their bioavailability differs.

Approved medical use

All US isotretinoin products share one indication: severe recalcitrant nodular acne, meaning many inflammatory nodules 5 mm or larger. The labels reserve it for patients who have not responded to conventional therapy, including systemic antibiotics, and who are not pregnant. Absorica is labeled for patients 12 years and older.

Product	Labeled dose	Food
Standard capsules (Accutane and generics)	0.5–1 mg/kg/day in two divided doses for 15–20 weeks; up to 2 mg/kg/day in adults with very severe, scarring or truncal disease	Must be taken with a meal
Absorica	0.5–1 mg/kg/day in two divided doses for 15–20 weeks; up to 2 mg/kg/day	With or without meals
Absorica LD	0.4–0.8 mg/kg/day in two divided doses for 15–20 weeks; up to 1.6 mg/kg/day	With or without meals

Other labeled dosing rules:

Once-daily dosing is not recommended, because its safety has not been established.
Treatment may stop early if the total nodule count falls by more than 70%.
A second course should not start until at least 2 months after the first, because acne can keep improving after treatment ends.
Long-term use, even at low doses, has not been studied and is not recommended.

The American Academy of Dermatology’s 2024 guideline gives oral isotretinoin a strong recommendation for acne that is severe, causes psychosocial burden or scarring, or fails standard oral or topical therapy (Reynolds et al., JAAD 2024).

What the research shows

Dose and response

A double-blind multicenter trial randomized 150 patients with treatment-resistant nodulocystic acne to 0.1, 0.5 or 1.0 mg/kg/day (Strauss et al., JAAD 1984). All three doses produced a highly significant response, with no significant difference in initial response between them. However, 42% of patients on 0.1 mg/kg/day needed retreatment, which led the authors to favor the higher doses. The label cites this dose-response work for the same conclusion.

Head-to-head with another isotretinoin capsule

Absorica’s approval trial randomized 925 people aged 12–54 with severe nodular acne to Absorica or another isotretinoin capsule, both taken with food. Dosing was 0.5 mg/kg/day for 4 weeks and then 1 mg/kg/day for 16 weeks (Absorica label):

Week 20 outcome	Absorica (n = 464)	Other isotretinoin capsule (n = 461)
Mean baseline nodule count	18.4	17.7
Mean reduction in nodules	−15.68	−15.62
At least 90% reduction in nodules	324 (70%)	344 (75%)

Cochrane review

A 2018 Cochrane review pooled 31 randomized trials with 3,836 participants aged 12–55 (Costa et al., Cochrane 2018). All but three trials had a high risk of bias in at least one area, and most of the evidence was rated low quality.

Comparison	Result
Isotretinoin vs oral antibiotics plus topicals: inflammatory lesion count (3 trials, 400 people)	No difference, RR 1.01 (95% CI 0.96–1.06); very low-quality evidence
Same comparison: physician-rated improvement (2 trials, 351 people)	RR 1.15 (95% CI 1.00–1.32), a possible small benefit
Same comparison: less serious side effects such as dry lips and skin	67% more common, RR 1.67 (95% CI 1.42–1.98)
0.1, 0.5 and 1 mg/kg/day for 20 weeks (one 150-person trial in severe acne)	58%, 80% and 90% reached a 95% drop in inflammatory lesions

The antibiotic comparisons enrolled people with moderate or severe acne. The authors said isotretinoin for acne that has not responded to antibiotics plus topical treatment needs further study.

Total dose and relapse

Relapse after a course is common. A prospective observational study followed 116 of 180 patients for 12 months after treatment, with doses set by their doctors (Blasiak et al., JAMA Dermatol 2013):

Cumulative dose	Relapse at 12 months
Under 220 mg/kg	47.4% (95% CI 32.3–63.0%)
220 mg/kg or more	26.9% (95% CI 18.3–37.8%)

The difference was significant (p = 0.03). Rash (retinoid dermatitis) was more common at the higher total dose: 53.8% vs 31.6%. Because this was not a randomized trial, it shows an association, not proof that higher totals cause fewer relapses.

Side effects and risks

Boxed warning: birth defects

Every isotretinoin label carries a boxed warning that the drug causes life-threatening birth defects and must not be used in pregnancy. The label states that any amount, even for a short time, carries an extremely high risk (Accutane label). Documented defects affect the skull, face, ears, eyes, brain, heart, thymus and parathyroid glands. Miscarriage is also more likely.

The classic study followed 154 pregnancies exposed to isotretinoin (Lammer et al., NEJM 1985):

Outcome	Number
Elective abortions	95
Spontaneous abortions	12
Infants with major malformations	21
Infants without major malformations	26
Relative risk of selected major malformations	25.6 (95% CI 11.4–57.5)

Exposed pregnancies still occur under iPLEDGE. FDA adverse event reports listed 6,740 pregnancies in people taking isotretinoin from 1997 to 2017. Reports peaked at 768 in 2006, the year iPLEDGE started, and ran at 218–310 per year after 2011 (Tkachenko et al., JAMA Dermatol 2019).

For male patients, the label says isotretinoin is found in semen, but a partner would receive about one million times less than a 40 mg oral dose.

The iPLEDGE program

Because of the birth-defect risk, isotretinoin is sold only through the iPLEDGE REMS (risk evaluation and mitigation strategy). Prescribers, pharmacies, wholesalers and patients must all be enrolled. Key requirements from the label:

Patients who can become pregnant need two negative pregnancy tests before the first prescription, and a negative test every month.
They must use two forms of contraception from one month before treatment until one month after, unless they commit to abstinence.
Each fill is limited to a 30-day supply, with no automatic refills.
No patient may donate blood during treatment or for one month afterward, or share the drug with anyone.

The label also warns that progestin-only “minipills” may be inadequate contraception during treatment.

Psychiatric effects

The label warns that isotretinoin may cause depression, psychosis and, rarely, suicidal thoughts, suicide attempts, suicide, and aggressive or violent behavior. Some patients’ depression went away when they stopped the drug and returned when they restarted it. The label tells patients to stop the drug and contact their prescriber if mood symptoms appear.

Population studies have not found an overall increase in risk:

A 2017 meta-analysis of 31 studies found no significant difference in change in depression scores vs other acne treatments (SMD −0.334, 95% CI −0.680 to 0.011). The prevalence of depression fell after treatment (RR 0.588, 95% CI 0.382–0.904). None of the included studies was randomized (Huang and Cheng, JAAD 2017).
A 2024 meta-analysis of 25 studies with 1,625,891 participants found no increase in psychiatric disorders overall (RR 1.08, 95% CI 0.99–1.19). The 1-year absolute risk of depression among users was 3.83% (95% CI 2.45–5.93%), and suicide attempts were slightly less common than in non-users at 2–4 years (Tan et al., JAMA Dermatol 2024).

The authors of the 2024 analysis still advised monitoring patients for mental distress, since population averages cannot rule out reactions in individuals.

Blood lipids, pancreas and liver

These are the most common lab changes, and they overlap with the effects of oral steroids such as oxandrolone, which also lower HDL and can raise liver enzymes. We found no studies of the two drug types taken together.

From the label’s clinical trials (Accutane label):

Finding	Frequency
Marked rise in triglycerides	About 25%
Fall in HDL cholesterol	About 15%
Rise in total cholesterol	About 7%
Mild to moderate rise in liver enzymes	About 15%

Triglycerides above 800 mg/dL have been reported. Acute pancreatitis, rarely fatal, has occurred with both high and normal triglycerides. Clinical hepatitis has also been reported. In trials, the lipid changes reversed after stopping.

Real-world rates of new abnormal results can be higher. In 13,772 patients in a Northern California health plan whose values were normal at baseline, new abnormalities developed in 44% for triglycerides, 31% for total cholesterol and 11% for transaminases. Moderate to severe changes were generally transient and reversible (Zane et al., Arch Dermatol 2006).

Muscle, joints and bone

These risks are relevant to people who train hard:

Muscle enzyme rises: in a trial of 924 people, about 24% had marked creatine kinase (CPK) rises of 350 U/L or more (Absorica label). Rare cases of rhabdomyolysis (severe muscle breakdown) have been reported, some linked to strenuous exercise.
Joint and muscle pain: about 16% of patients in one trial had musculoskeletal symptoms. In children and teens, 29% had back pain and 22% had joint pain.
Bone: in a 217-patient adolescent study of a single course, most had no meaningful change in bone density, but about 8% lost more than 4% at the lumbar spine. Bone thickening (hyperostosis), calcified tendons and ligaments, and early growth-plate closure have been reported, especially with higher doses or longer use.

Other label warnings

Raised pressure in the skull (pseudotumor cerebri): some cases involved tetracycline antibiotics, so the two should not be combined.
Severe skin reactions: including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Eyes and ears: dry eyes, corneal opacities, decreased night vision (sometimes persistent), and hearing loss or tinnitus.
Bowel: the label warns of inflammatory bowel disease. A 2023 meta-analysis of 8 studies with 2,522,422 participants found no increased odds of IBD (OR 1.01, 95% CI 0.80–1.27) (Yu et al., Am J Clin Dermatol 2023).
Sexual function: the Absorica label lists sexual dysfunction, including erectile dysfunction and decreased libido, which may continue after treatment stops.
Skin procedures: waxing and resurfacing (dermabrasion, laser) should be avoided during treatment and for at least 6 months afterward because of scarring risk.
Blood counts and sugar: low white cell counts, rare agranulocytosis, and problems with blood sugar control have been reported.

Dry lips (cheilitis) and dry skin are near-universal: in the high-dose cohort study, almost all patients developed both (Blasiak et al., JAMA Dermatol 2013).

Interactions

Drug or supplement	Label guidance
Vitamin A supplements	Avoid, because the effects add up
Tetracyclines (doxycycline, minocycline)	Avoid, because of pseudotumor cerebri cases
Progestin-only “minipill”	May be inadequate contraception
St. John’s wort	Possible loss of hormonal contraceptive effect; pregnancies reported
Systemic corticosteroids, phenytoin	Use caution, because both can harm bone
Combined oral contraceptive (norethindrone/ethinyl estradiol)	No clinically relevant change in hormone levels in a 31-patient study

Who should not use it

The label lists these contraindications and restrictions:

pregnancy, or anyone who may become pregnant without meeting iPLEDGE requirements;
breastfeeding;
allergy to isotretinoin or any capsule ingredient.

Monitoring

The labels call for the following tests:

Pregnancy tests: before treatment, monthly, at the end of the course, and one month after.
Fasting lipids: before treatment and then at intervals until the response is known, usually within 4 weeks. Testing should wait 36 hours after alcohol.
Liver function tests: before treatment and then weekly or every two weeks until the response is known.

The Zane study found that routine blood-count monitoring added little without a clinical reason to suspect a problem.

Legal status and use outside medicine

United States: prescription only. The label states that isotretinoin must not be prescribed, dispensed or obtained through the internet or any other route outside iPLEDGE. It is not an anabolic steroid and is not listed in Schedule III (21 CFR 1308.13).
Sport: isotretinoin is not named on the WADA 2026 Prohibited List, and retinoids are not among the listed classes.

Key takeaways

An acne drug, not a performance drug. Isotretinoin is a vitamin A–related retinoid approved since 1982 for severe nodular acne that fails antibiotics. It shrinks the sebaceous glands and often gives lasting remission after one 15–20 week course.
Severe birth-defect risk. Exposure in pregnancy raised the risk of selected major malformations about 25-fold in the landmark study, which is why it is sold only through iPLEDGE.
Labs change often. About a quarter of trial patients had marked triglyceride rises, and about 15% had liver enzyme rises. These overlap with the effects of oral steroids, and the combination has not been studied.
Relevant to heavy training. About 24% of patients in one trial had marked creatine kinase rises, and rare rhabdomyolysis has been linked to strenuous exercise.
Mood warnings remain. Large meta-analyses have not found higher population rates of depression or suicide, but the label still requires monitoring and stopping if symptoms appear.
Food and formulation matter. Standard capsules absorb more than twice as well with a high-fat meal. Absorica and Absorica LD are less food-dependent and are not interchangeable mg for mg.

Sources

JG Pharma Inc. Accutane (isotretinoin capsules USP) prescribing information, ANDA 202099. Issued 09/2022. DailyMed.
Sun Pharmaceutical Industries. Absorica and Absorica LD (isotretinoin capsules) prescribing information, NDA 021951 and NDA 211913. DailyMed.
Food and Drug Administration. Determination that ACCUTANE (isotretinoin) capsules, 10 milligrams, 20 milligrams, and 40 milligrams, were not withdrawn from sale for reasons of safety or effectiveness. Federal Register. July 7, 2010;75:39024 (FR Doc 2010-16439). Federal Register.
Food and Drug Administration. Hoffmann-La Roche Inc.; withdrawal of approval of a new drug application. Federal Register. November 22, 2010;75:71135 (FR Doc 2010-29348). Federal Register.
National Center for Biotechnology Information. PubChem Compound Summary: Isotretinoin (CID 5282379). PubChem.
Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med. 1979;300(7):329–333. PubMed.
Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10(3):490–496. PubMed.
Nelson AM, Zhao W, Gilliland KL, et al. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Invest. 2008;118(4):1468–1478. PubMed.
Melnik B, Jansen T, Grabbe S. Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges. 2007;5(2):110–117. PubMed.
Costa CS, Bagatin E, Martimbianco ALC, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev. 2018;11(11):CD009435. PubMed.
Blasiak RC, Stamey CR, Burkhart CN, et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013;149(12):1392–1398. PubMed.
Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1–1006.e30. PubMed.
Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837–841. PubMed.
Tkachenko E, Singer S, Sharma P, et al. US Food and Drug Administration reports of pregnancy and pregnancy-related adverse events associated with isotretinoin. JAMA Dermatol. 2019;155(10):1175–1179. PubMed.
Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;76(6):1068–1076.e9. PubMed.
Tan NKW, Tang A, MacAlevey NCYL, et al. Risk of suicide and psychiatric disorders among isotretinoin users: a meta-analysis. JAMA Dermatol. 2024;160(1):54–62. PubMed.
Zane LT, Leyden WA, Marqueling AL, et al. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 2006;142(8):1016–1022. PubMed.
Yu CL, Chou PY, Liang CS, et al. Isotretinoin exposure and risk of inflammatory bowel disease: a systematic review with meta-analysis and trial sequential analysis. Am J Clin Dermatol. 2023;24(5):721–730. PubMed.
World Anti-Doping Agency. 2026 Prohibited List. WADA 2026 Prohibited List.
Code of Federal Regulations. 21 CFR 1308.13, Schedule III. 21 CFR 1308.13.

Accutane (Isotretinoin)